Core Insights - Plus Therapeutics reported a quarterly loss of 0.51, representing an earnings surprise of -31.37% [1] - The company generated revenues of 1.31 million a year ago [2] - Plus shares have increased by approximately 27.8% since the beginning of the year, contrasting with a -2.9% decline in the S&P 500 [3] Company Outlook - The future performance of Plus Therapeutics will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][5] - Current consensus EPS estimate for the upcoming quarter is -1.7 million, while for the current fiscal year, it is -5.4 million [7] - The estimate revisions trend for Plus is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Plus belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Indivior PLC, is expected to report quarterly earnings of $0.22 per share, reflecting a year-over-year decline of 40.5% [9]
Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates